Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2017 | Pages:
74 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Cough - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cough - Pipeline Review, H1 2017, provides an overview of the Cough (Respiratory) pipeline landscape. Cough is a common reflex action that aims to clear the throat of mucus or foreign irritants. Dry cough, chronic cough and whooping cough (also known as pertussis) are distinct types of cough. Symptoms include runny or stuffy nose, hoarseness, wheezing and shortness of breath, heartburn or a sour taste in mouth and rarely coughing up blood. The predisposing factors include asthma, chronic obstructive pulmonary disease, cigarette smoking, lung diseases such as bronchiectasis, interstitial lung disease, or tumors, lung infections such as pneumonia or acute bronchitis and allergic rhino sinusitis. Treatment includes cough suppressants, oral expectorants, and topical (externally applied) drugs. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cough - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Cough (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Cough (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Cough and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical, Discovery and Unknown stages are 2, 1, 6, 9, 2 and 4 respectively. Cough (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Cough (Respiratory). - The pipeline guide reviews pipeline therapeutics for Cough (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Cough (Respiratory) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Cough (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Cough (Respiratory) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Cough (Respiratory). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Cough (Respiratory) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Cough - Overview Cough - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Cough - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Cough - Companies Involved in Therapeutics Development Afferent Pharmaceuticals Inc Alitair Pharmaceuticals Inc Alveonix AG AstraZeneca Plc BELLUS Health Inc Charleston Laboratories Inc Conrig Pharma ApS Daewoong Pharmaceutical Co Ltd Hyundai Pharmaceutical Co Ltd NeRRe Therapeutics Ltd Orbis Biosciences Inc Patara Pharma Inc PhytoHealth Corp Pila Pharma AB Vernalis Plc Cough - Drug Profiles AF-219 - Drug Profile Product Description Mechanism Of Action R&D Progress Ax-8 - Drug Profile Product Description Mechanism Of Action R&D Progress benzonatate - Drug Profile Product Description Mechanism Of Action R&D Progress BLU-5937 - Drug Profile Product Description Mechanism Of Action R&D Progress CCP-05 - Drug Profile Product Description Mechanism Of Action R&D Progress CCP-06 - Drug Profile Product Description Mechanism Of Action R&D Progress CCP-07 - Drug Profile Product Description Mechanism Of Action R&D Progress CCP-08 - Drug Profile Product Description Mechanism Of Action R&D Progress CLAT-313 - Drug Profile Product Description Mechanism Of Action R&D Progress codeine + guaifenesin - Drug Profile Product Description Mechanism Of Action R&D Progress cromolyn sodium - Drug Profile Product Description Mechanism Of Action R&D Progress DWJ-1340 - Drug Profile Product Description Mechanism Of Action R&D Progress guaifenesin + hydrocodone - Drug Profile Product Description Mechanism Of Action R&D Progress guaifenesin ER - Drug Profile Product Description Mechanism Of Action R&D Progress lesogaberan - Drug Profile Product Description Mechanism Of Action R&D Progress levodropropizine CR - Drug Profile Product Description Mechanism Of Action R&D Progress ORB-110 - Drug Profile Product Description Mechanism Of Action R&D Progress orvepitant maleate - Drug Profile Product Description Mechanism Of Action R&D Progress PHCA-01 - Drug Profile Product Description Mechanism Of Action R&D Progress S-1226 - Drug Profile Product Description Mechanism Of Action R&D Progress ST-015 - Drug Profile Product Description Mechanism Of Action R&D Progress ST-016 - Drug Profile Product Description Mechanism Of Action R&D Progress ST-018 - Drug Profile Product Description Mechanism Of Action R&D Progress XEND-0501 - Drug Profile Product Description Mechanism Of Action R&D Progress Cough - Dormant Projects Cough - Discontinued Products Cough - Product Development Milestones Featured News & Press Releases Dec 21, 2016: FDA accepts CCP-08 NDA for full review Sep 07, 2016: Patara Pharma Announces Positive Phase 2 Results for the Treatment of Refractory Chronic Cough in Patients with Idiopathic Pulmonary Fibrosis Sep 06, 2016: Vernalis annopunces that FDA accepts CCP-07 NDA for full review Jul 08, 2016: Vernalis Announces Successful Completion of CCP-08 Pivotal Multiple-Dose Comparative Bioavailability Study May 16, 2016: Afferent Pharmaceuticals Presents Updated Positive Results with AF-219 from Phase 2B Chronic Cough Study at the 2016 American Thoracic Society International Conference May 03, 2016: Patara Pharma Appoints Biotechnology Industry Leader John Schmid to Board of Directors Apr 25, 2016: Afferent Pharmaceuticals Announces Presentation of Chronic Cough Clinical Data at the Upcoming American Thoracic Society 2016 International Conference Apr 14, 2016: Vernalis Announces Successful Completion of CCP-07 Pivotal Multiple-Dose Comparative Bioavailability Study Apr 13, 2016: Vernalis Announces Successful Completion of CCP-08 Pivotal Single-Dose Comparative Bioavailability Study Dec 21, 2015: Vernalis Announces Successful Completion of CCP-07 Pivotal Single-Dose Comparative Bioavailability Study Oct 12, 2015: Vernalis announces start of CCP-08 12 month stability testing Sep 28, 2015: Afferent Pharmaceuticals Announces Positive Results in Phase 2b Chronic Cough Trial Jul 01, 2015: Spriaso Announces Approval of New Drug Application for the Long Acting Codeine Antitussive With a Popular Anti-Histamine Jun 11, 2015: Vernalis announces CCP-07 starts 12 month stability testing Nov 25, 2014: Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough Is Published In The Lancet Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Cough, H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Cough - Pipeline by Afferent Pharmaceuticals Inc, H1 2017 Cough - Pipeline by Alitair Pharmaceuticals Inc, H1 2017 Cough - Pipeline by Alveonix AG, H1 2017 Cough - Pipeline by AstraZeneca Plc, H1 2017 Cough - Pipeline by BELLUS Health Inc, H1 2017 Cough - Pipeline by Charleston Laboratories Inc, H1 2017 Cough - Pipeline by Conrig Pharma ApS, H1 2017 Cough - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017 Cough - Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2017 Cough - Pipeline by NeRRe Therapeutics Ltd, H1 2017 Cough - Pipeline by Orbis Biosciences Inc, H1 2017 Cough - Pipeline by Patara Pharma Inc, H1 2017 Cough - Pipeline by PhytoHealth Corp, H1 2017 Cough - Pipeline by Pila Pharma AB, H1 2017 Cough - Pipeline by Vernalis Plc, H1 2017 Cough - Dormant Projects, H1 2017 Cough - Dormant Projects, H1 2017 (Contd..1), H1 2017 Cough - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
